Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
15 evidence topics · 12 sources
Warnings and precautions
Approved prescribing information, boxed warnings, contraindications, and REMS
Not applicable.
Subcutaneous formulation: adverse event profile in the phase 2 trial
“The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: discontinuation and serious adverse events in the phase 2 trial
“In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug. The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: adverse events of special interest and treatment discontinuation by dose in the phase 2 trial
Subcutaneous formulation: gastrointestinal adverse events with a 5.0 mg starting dose
“Nausea was highest in the first week in the 15 mg dose group; this group had a 5.0 mg starting dose, rather than the 2.5 mg starting dose in all other treatment groups” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GI AEs were generally observed early in the study and subsided over time” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: heart rate change at week 13 in the phase 2 trial
Subcutaneous formulation: anti-drug antibodies in the phase 2 trial
Subcutaneous formulation: gallstone obstruction and hypoglycemia in the phase 1 multiple ascending dose study
Subcutaneous formulation: tolerability with two-week titration steps and with every-other-week or monthly maintenance
Oral formulation: discontinuation and gastrointestinal adverse events in the phase 2 trial
Oral formulation: treatment discontinuation by dose in the phase 2 trial
Oral formulation: serious and drug-related adverse events by cohort in the phase 1 multiple ascending dose study
| Event, number of subjects (%) | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
|---|---|---|---|---|---|---|---|---|---|---|
| Drug related TEAEs | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |